Introduction
Obesity is recognised as a major yet preventable global health concern, with rising prevalence across both adult and paediatric populations. It is strongly associated with insulin resistance, cardiovascular disease risk, and progression towards diabetes mellitus. A significant proportion of South Asian populations demonstrate insulin resistance, indicating a substantial metabolic burden and increased susceptibility to related disorders.1
Gut microbiota and metabolic dysfunction
Alterations in gut microbiota composition, referred to as dysbiosis, have been associated with a wide range of intestinal and extraintestinal conditions. Intestinal manifestations include inflammatory bowel disease, irritable bowel syndrome, and coeliac disease, while extraintestinal associations extend to allergic disorders, asthma, metabolic syndrome, cardiovascular disease, and obesity. This highlights the systemic influence of gut microbial imbalance in metabolic and inflammatory pathways.2
Panchakarma and metabolic restoration
- Panchakarma represents a structured system of five internal purification procedures designed to eliminate metabolic waste through natural routes, supporting restoration of physiological balance. This process of purification (Śodhana) is performed in preparatory, main, and post-procedural phases, facilitating systemic homeostasis, rejuvenation, and improved therapeutic response to interventions.
- Although clinical applications have demonstrated benefits in metabolic conditions such as obesity and diabetes mellitus, mechanistic interpretations remain less explored due to conceptual differences between traditional and contemporary biomedical frameworks. Within Ayurvedic understanding, Panchakarma is positioned as a preventive, curative, and health-promoting intervention, particularly relevant in chronic metabolic dysfunction.
Obesity as a Santarpanajanya vikara
- Obesity is classified as a Santarpanajanya Vikara, arising from excessive nutritional accumulation. It is characterised by Srotorodha (obstruction in systemic channels), impaired Agni, and imbalance of Tridosha. Among Panchakarma modalities, Virechana Karma (therapeutic purgation) is specifically indicated for such conditions.
- Virechana Karma supports clearance of Srotoavarodha, restoration of digestive and metabolic fire (Agni), and re-establishment of doshic equilibrium. This contributes to improved metabolic regulation and systemic balance in obesity management.
Metabolic effects of Virechana karma
Virechana Karma, along with its preparatory procedures, is associated with improvement in fat metabolism and correction of metabolic disturbances linked to insulin resistance. It is observed to contribute to reductions in body weight, BMI, serum triglycerides, and blood glucose levels. Additionally, it supports reduction of lipid storage in adipose tissue, thereby improving insulin sensitivity at receptor sites in skeletal muscle.3
Conclusion
Panchakarma, particularly Virechana Karma, provides a structured approach to metabolic regulation in obesity through systemic purification and restoration of physiological balance. Its role in addressing insulin resistance, lipid metabolism, and channel obstruction positions it as a relevant therapeutic strategy within integrative approaches to obesity and associated metabolic disorders.
References:
1. Sawant A, Mankeshwar R, Shah S, et al. Prevalence of metabolic syndrome in urban India. Cholesterol. 2011;2011:920983. doi:10.1155/2011/920983. https://pmc.ncbi.nlm.nih.gov/articles/PMC3114375/
2. Peterson CT, Lucas J, John-Williams LS, et al. Identification of Altered Metabolomic Profiles Following a Panchakarma-based Ayurvedic Intervention in Healthy Subjects: The Self-Directed Biological Transformation Initiative (SBTI). Sci Rep. 2016;6:32609. Published 2016 Sep 9. doi:10.1038/srep32609. https://pmc.ncbi.nlm.nih.gov/articles/PMC5017211/
3. Chaturvedi A, Nath G, Yadav VB, et al. A clinical study on Virechana Karma (therapeutic purgation) over the gut flora with special reference to obesity. Ayu. 2019;40(3):179-184. doi:10.4103/ayu.AYU_302_19. https://pmc.ncbi.nlm.nih.gov/articles/PMC7685265/#sec1-5